Pediatric clinical trials not going overseas – study
















NEW YORK (Reuters Health) – Despite some concerns that medical studies involving children could make an ethically dubious shift to developing nations, a new study suggests that’s not happening.


It’s really only in the last decade that clinical trials – even in the U.S. and Europe – have started to focus on children, said Dr. Dianne Murphy, director of the U.S. Food and Drug Administration (FDA) Office of Pediatric Therapeutics.













Since children cannot give informed consent to enter a study (their parents have to do it), kids have historically been left out of clinical trials testing vaccines, drugs and other therapies.


But that’s a problem, Murphy explained, because children are not small adults, and study results from adults cannot simply be extended to them.


“We don’t know if we’re giving them the right dose, or if it’s even going to be effective,” Murphy explained.


So pediatric clinical trials are necessary. But since most children are, fortunately, healthy, researchers have to cast a wider net for study participants.


“You do have to reach out to more countries and more locations,” Murphy said.


And that has led some to question whether there could be an inappropriate shift to countries where ethical guidelines – like making sure parents give truly informed consent – might not be closely monitored.


In the new study, however, Murphy and her colleagues found that the number of pediatric clinical trials in developing countries has actually declined in recent years. And the U.S. remains, by far, the most common trial location.


Of 346 pediatric trials the FDA reviewed, the U.S. participated in 86 percent, providing three-quarters of the patients. Less developed and transitional countries, like Mexico, Brazil and India, took part in 22 percent and accounted for 10 percent of all kids involved.


The figures come from trials submitted to the FDA in support of therapies approved between 2007 and 2010.


Developing nations, the agency found, played a smaller role in those trials than they had just a few years earlier.


In an earlier study of trials submitted between 2002 and 2007, the FDA found that developing countries took part in 38 percent of trials, and accounted for almost one-quarter of patients.


Those numbers will naturally shift depending on the diseases and treatments being studied in a given time period, Murphy noted.


If there are more trials testing vaccines or treatments for infectious disease, developing nations will tend to be more involved. And that’s appropriate, Murphy said, because those diseases are a far bigger problem in developing countries.


“Children shouldn’t be in a trial unless there’s an opportunity for them to benefit,” Murphy said.


The researchers didn’t find evidence that kids in developing countries were being recruited into trials for diseases that are irrelevant to them. Of children enrolled in Mexico, for example, 97 percent were involved in vaccine trials.


In addition, most trials being done in developing countries (75 percent) were also running in wealthy ones.


Murphy said the FDA is taking steps to ensure that pediatric trials are being done appropriately. “For one,” she noted, “everyone should be aware that we’re reviewing this. That alone is important.”


But she said the agency also offers training to regulators in other countries, and has regular conference calls with officials in developing nations to help them with “in-the-weeds kinds of questions.”


“These conversations, particularly for (trials with) children, are very important,” Murphy said.


Continuing to do trials involving kids is also vital, according to Murphy.


“If we don’t, then your child becomes an experiment of one,” she said, noting that research suggests that products that work for adults’ ills do not work for children about one-fifth of the time.


SOURCE: http://bit.ly/UwOXbC Pediatrics, online November 5, 2012.


Medications/Drugs News Headlines – Yahoo! News



Read More..

Wall Street left to rebuild Obama ties after backing Romney
















(Reuters) – Wall Street firms gambled on Mitt Romney and lost.


Now, faced with the prospect of even tougher regulations in President Barack Obama‘s second term, their stocks paid the price. Shares of Goldman Sachs Group, JPMorgan Chase & Co and Citigroup dropped 5 percent, Bank of America lost 6 percent and Morgan Stanley fell 7 percent in midday trading on Wednesday.













“This is the triumph of the regulators,” said Terry Haines, senior analyst at Potomac Research Group in Washington and a former staff director of the U.S. House of Representative’s Financial Services Committee.


Obama’s win is bad news for financial firms, particularly big bank holding companies, which face regulations still being written to implement the 2010 Dodd-Frank reform law, Haines said. “The Administration’s regulatory approach has triumphed and is going to continue for some years,” said Haines.


After backing Romney nearly across the board, the financial services industry must quickly reverse course and seek to mend ties, Haines and other public policy experts said.


But there were mixed signs of accommodation in the wake of Obama’s re-election, with some bankers maintaining their critique of the Democratic President’s regulatory policies.


“He will continue to increase regulation, demonize and vilify businesses, and spend a lot of money, and tax people, and so forth,” said Dick Kovacevich, former CEO of Wells Fargo & Co and supporter of Republican challenger Romney.


On the other side, Scott Sperling, co-president of private equity firm Thomas H Lee Partners, reached out towards Obama, who he abandoned for Romney in 2012. “It is incumbent on us to work with the administration in a productive way to deal with these issues,” he said.


Wall Street firms are also worried about Elizabeth Warren, whose victory in the Massachusetts Senate race may galvanize her to push for more regulations on bank lending to protect consumers. Warren was instrumental in creating the Consumer Financial Protection Bureau, which critics say could weigh down the economy with new regulations.


“I think the Obama win, along with Elizabeth Warren, will lead to more accountability and tighter regulation on Wall Street,” said Chris Tobe, who advises pension plans as a principal at Stable Value Consultants and is a trustee of the Kentucky state pension fund. “Especially after a big shift to Romney from Wall Street, Obama I believe will be less likely to hold back on regulation this term.”


Republican former regulators sought to downplay Warren’s impact. “Wall Street has a decided enemy on its hands,” said Harvey Pitt, who ran the Securities and Exchange Commission under President George W. Bush. Still, Warren’s election by itself “isn’t going to have a very dramatic impact on anything,” he said. “She’s just one of 100 senators.”


People working in the U.S. securities and investment industry gave $ 20 million to Romney’s campaign, versus $ 6 million to Obama, according to the Center for Responsive Politics. Four years ago, Obama received $ 16 million and Republican nominee John McCain only attracted $ 9 million.


Obama’s administration has still not finished writing many of the most important rules called for in the Dodd Frank law, passed after the U.S. financial system nearly collapsed in 2008, forcing taxpayers to pour hundreds of billions of dollars into banks’ coffers.


Many Americans believe the financial crisis was caused by banks’ terrible judgment in areas like mortgage lending and securitization. Public support is strong for laws designed to make the financial system safer, even if bank profits suffer.


A 2010 Gallup poll showed that Dodd-Frank was Obama’s most popular law, exceeding healthcare reform, for example. Few Washington lobbyists thought that Romney could fully repeal Dodd-Frank, because public support for the law is too high.


RELATIONS WITH REGULATORS


Banks must now focus on softening regulations to the extent they can. Among the financial industry’s top complaints are the Volcker rule, which prevents banks from making big bets in financial markets with their own money, and the Durbin Amendment, which limits the fees they can charge merchants for processing debit-card transactions.


Banks also want to scale back capital requirements, which cut into the returns banks can earn on their equity capital.


The industry had hoped to weaken the Consumer Financial Protection Bureau through steps like changing its structure to be headed by Democrat and Republican commissioners, but these steps are unlikely to gain much traction, analysts said.


“What I was told last night by Obama’s win is, there will be no change to the CFPB in 2013,” said Isaac Boltansky, a policy analyst at Compass Point Research & Trading in Washington.


SECOND-TERM APPOINTMENTS


Some banking industry lobbyists say their focus will be on the key regulators Obama is expected to name in his second term.


Major power players under Obama, including Treasury Secretary Timothy Geithner, are expected to step down, offering Wall Street a chance to reset relations.


Chairmen determine agendas at agencies such as the SEC and Commodity Futures Trading Commission (CFTC), so Obama’s choices to fill any open spots could affect how quickly new rules are implemented.


“If there was a different chair who had a different agenda, you could slow things down,” said Bart Chilton, a Democratic commissioner at the Commodity Futures Trading Commission.


One possible replacement for Geithner, who has said he will not stay for a second Obama term, is White House Chief of Staff Jack Lew, a former Citigroup banker.


“I hope Obama puts someone in who understands fiscal issues and who will have stature to work on the Hill to negotiate some type of package on fiscal reform,” said Sheila Bair, former Federal Deposit Insurance Corp chairman.


SEC Chairman Mary Schapiro’s term does not expire until June 2014, but speculation about her departure has been swirling for well over a year. Last month, she attempted to shoot down the rumors, saying she had not thought about her post-SEC plans.


SEC watchers speculate the job could go to SEC Commissioner Elisse Walter, a close friend of Schapiro’s and a former executive at the Financial Industry Regulatory Authority, an industry-funded watchdog.


CFTC Chairman Gary Gensler’s term technically expired in April. He is allowed to stay on as chairman until the end of 2013 and his renomination is an open question.


Gensler has been assailed by Republicans over his implementation of Dodd-Frank and criticized by lawmakers on both sides of the aisle following the collapse of futures brokerages MF Global and Peregrine Financial Group.


FISCAL CLIFF


Much of Wall Street‘s regulatory agenda, however, is set to take a backseat in the short term due to the looming fiscal cliff — a package of tax increases and federal spending cuts that will begin in January unless lawmakers act.


Bankers fear an impasse in solving the issue could spark an economic downturn that would hurt the industry.


In the longer term, banking lobbyists and other opponents of Dodd-Frank acknowledge that much is in the hands of rulemakers, and the best they can do is to try to beat back some rules with technicalities.


Paul Atkins, a Republican and former SEC commissioner, said he expects Dodd-Frank reform critics may have some success making narrow legal challenges and seeking to throttle reforms through congressional oversight.


“Dodd-Frank assigned a lot of powers to the regulatory agencies, so there is not much that Congress can do,” he said.


“I expect that the Republican House would keep the pressure on through hearings, like they are doing now. People will also certainly take the fight to the courts.” (Reporting By Emily Stephenson and Sarah N. Lynch in Washington, D.C., Rick Rothacker in Charlotte, Lauren LaCapra, Dan Wilchins, Olivia Oran and Katya Wachtel in New York, and Aaron Pressman and Ross Kerber in Boston; Writing by Aaron Pressman and Greg Roumeliotis; Editing by Paritosh Bansal, Tiffany Wu, Richard Pullin, Maureen Bavdek and Tim Dobbyn)


Business News Headlines – Yahoo! News



Read More..

Merkel says Germany, Britain must work together on EU
















LONDON (Reuters) – Germany and Britain must cooperate to work round their differences on the European Union‘s long-term spending plans, German Chancellor Angela Merkel said on Wednesday.


“Despite differences that we have it is very important for me that the UK and Germany work together,” Merkel said through a translator before a meeting in London with Prime Minister David Cameron to discuss the EU‘s 2014-2020 budget.













“We always have to do something that will stand up to public opinion back home. Not all of the expenditure that has been earmarked has been used with great efficiency … We need to address that,” she said.


EU leaders meet in Brussels on November 22-23 to try to secure a seven-year budget for the 27-nation bloc amid signs of differences of opinion over what action should be taken.


(Reporting by Peter Griffiths; Editing by Andrew Osborn)


Europe News Headlines – Yahoo! News



Read More..

Amazon’s offers monthly option on Prime, challenging Netflix
















SAN FRANCISCO (Reuters) – Amazon.com Inc is testing a new monthly option for its popular Prime video-streaming service as the world’s largest Internet retailer steps up competition with Netflix Inc.


Prime typically costs $ 79 a year in the United States for free two-day shipping, free video streaming and access to Amazon‘s Kindle e-book lending library. The company is now offering the service for $ 7.99 a month on its website, which works out to $ 95.88 a year, but at that rate it can be purchased strictly on a month-to-month basis.













The monthly option is more comparable to Netflix’s streaming video subscription, which also costs $ 7.99 a month but does not come with free shipping and an e-book library. Another streaming rival, Hulu, also charges $ 7.99 a month.


An Amazon spokesman said the monthly Prime option was a test and declined to comment further.


Netflix and Hulu offer greater video selection than Amazon, though Amazon is spending hundreds of millions of dollars buying more content from Hollywood and TV studios.


“As Amazon continues to add movie and TV content to Prime, we see it likely adding more competitive pressure to the legacy online video services,” Colin Sebastian, an analyst at R.W. Baird, wrote in a note to investors on Tuesday.


Netflix shares fell 2.5 percent to $ 76.27 in afternoon trading on Tuesday. Amazon shares climbed 1.1 percent to $ 237.01.


Amazon’s new monthly Prime option coincides with the holiday shopping season, giving shoppers a way to use the two-day shipping service for gifts without the annual obligation, Sebastian noted.


“While one risk for Amazon is that consumers use Prime for just one month to take advantage of free shipping on large purchases, the test could also reveal that a ready market for alternative pricing and serve as a new customer acquisition tool,” the analyst wrote.


(Reporting By Alistair Barr; Editing by Leslie Adler)


Gadgets News Headlines – Yahoo! News



Read More..

Sharon Osbourne has double mastectomy: magazine
















LONDON (Reuters) – British celebrity Sharon Osbourne has had a double mastectomy after discovering she was carrying a gene that increased the risk of her developing breast cancer, she told Hello! magazine in an interview published on Monday.


Osbourne, 60, told the publication that the decision was a “no-brainer” in the end.













“As soon as I found out I had the breast cancer gene, I thought: ‘The odds are not in my favor’,” she said in remarks that also ran in the Daily Mirror tabloid.


“I’ve had cancer before and I didn’t want to live under that cloud: I decided to just take everything off, and had a double mastectomy.”


Osbourne, who put the eccentric life of her family on view in the reality TV series “The Osbournes”, said she did not want to spend the rest of her life with “that shadow hanging over me.


“I want to be around for a long time and be a grandmother to Pearl,” she added, referring to her son Jack’s first child.


“I didn’t even think of my breasts in a nostalgic way, I just wanted to be able to live my life without that fear all the time. It’s not ‘pity me’, it’s a decision I made that’s got rid of this weight that I was carrying around.”


Osbourne raised her profile by appearing as a judge on successful talent shows “The X Factor” and “America’s Got Talent”. She is married to heavy metal singer Ozzy Osbourne.


Her London publicist referred Reuters to the interview which ran in Hello! and the Daily Mirror when asked to confirm the news.


(Reporting by Mike Collett-White, editing by Paul Casciato)


Celebrity News Headlines – Yahoo! News



Read More..

Heart devices often approved without comparisons
















NEW YORK (Reuters Health) – Many new heart devices, such as valves and stents, are approved for use by the U.S. Food and Drug Administration (FDA) without good studies showing that they offer any benefits beyond existing treatments, according to a new study.


“This really leaves open the question of, ‘are you better off with this new device or whatever conventional therapy is already?’” said Dr. Rita Redberg, one of the authors of the study and a professor at the University of California, San Francisco.













Given that devices often require surgery, “from a patient point of view, you’re taking a lot more risk with a device, so the harms are potentially much greater,” added Redberg, whose team published the work in the Journal of the American Medical Association. “So it’s really very important to know that the device is an improvement over what you could have had.”


High-risk heart devices, which include implanted defibrillators, mechanical pumps and tubes called stents, go through an approval process called “premarket approval,” which includes a more stringent review of the evidence than for less risky devices.


However, the requirements for the approval of devices in general are less strict than for drugs.


The FDA requires two studies comparing the drug to a “control” – typically, the current standard of care or a fake pill called a placebo – before it will approve a drug.


For first-of-a-kind devices, FDA does require controlled trials, FDA spokeswoman Michelle Bolek told Reuters Health by email. However, the agency does not have such demands for devices that aren’t first-of-a-kind, and approval can be given without direct comparisons to controls, depending on the use of the device and the extent of experience doctors have had with it.


The FDA said there are good reasons why comparing new devices to other treatments or older generations of a product might not be feasible or ethical.


“And, requiring them could significantly and unnecessarily delay patient access to critical new technology,” Bolek added.


COMPARATIVE EFFECTIVENESS RESEARCH


Recent studies have found that sometimes patients are given newer and more expensive products without a clear indication that they’re better off for it (see Reuters report of February 28, 2012 and Reuters Health report of July 9, 2012).


The 2010 Patient Protection and Affordable Care Act, commonly called Obamacare, established the Patient-Centered Outcomes Research Institute, which funds research on comparing the effectiveness of different approaches to medical care.


To see how often heart devices are compared to existing therapies as part of the approval process, Redberg and her colleagues collected information from the FDA on all high-risk device approvals from 2000 to 2011.


They found that 40 percent of approved devices had been in studies comparing them to other treatments.


The comparison treatment could be an older generation of the same implant, a medication or a surgical procedure.


The rest of the approved devices relied on either the results from other studies in which controls were used, but the new device was not compared head-to-head with other treatments; from expectations of how well the device should work; or from research with no comparisons.


“We were surprised and disappointed,” said Redberg, who is also editor of the Archives of Internal Medicine and a member of the FDA’s Drug Administration Circulatory System Devices Panel. “We had already seen (in a previous study) there wasn’t as many randomized controlled trials as one would hope for devices, but we didn’t appreciate it until we looked at the data.”


SOMETIMES JUSTIFIABLE?


Some devices were less likely to have been compared to a conventional therapy than others.


Ventricular assist devices, for instance, used in severe cases of heart failure, were approved without any comparison to another therapy, but this could be justified, said Dr. David Brown, a professor at Stony Brook University in New York, who was not involved in the study.


“People are near death when they need the device, and it may not be ethical or practical to design a trial that compares it to something else,” he said.


“However, if you look at most of the devices in the other categories, they’re not anywhere near being performed in people who don’t have other options,” Brown told Reuters Health.


For instance, there are alternatives to new cardiac stents, pacemakers and defibrillators, such as drugs or other versions of the same devices, he pointed out.


Yet only about four out of 10 approvals for these types of devices included studies that compared them to existing treatments.


The FDA’s Bolek said the information Redberg’s group used to evaluate the studies conducted to get a device approved “does not reflect all of the data reviewed by the FDA in a (premarket approval) submission.”


Bolek said FDA weighs the quality of studies and their results, tests performed outside of the clinic and data monitoring committees.


Congress, Bolek said, has authorized the FDA to take the “least burdensome provision” to approve devices, to ensure that patients are not denied early access to new medical technology.


Dr. Ron Waksman, the associate director of the division of cardiology at the MedStar Washington Hospital Center, said the study does not differentiate between new products and slight improvements on already-approved devices.


“You don’t need to…for every change and iteration, do a clinical randomized trial” said Waksman, who was not part of the study but has been a consultant to medical device companies.


Still, Dr. William Boden at the Albany VA Stratton Medical Center said the different requirements for drug and device approvals is “egregious.”


“I think (the study) really elucidates the fact that there is just an unfortunate double standard, where there is a lack of transparency and a critical need for more comparative effectiveness evaluation before these devices come to market,” said Boden, who did not participate in the current research but whose research has been funded by pharmaceutical companies.


Brown said consumers should express their concerns about a lack of comparative effectiveness studies to their representatives in Congress.


SOURCE: http://bit.ly/Uge4Fb Journal of the American Medical Association, online November 5, 2012.


Medications/Drugs News Headlines – Yahoo! News



Read More..

Suspect Voter Fraud? Romney’s Campaign Has an App for That
















Tens of thousands of volunteer poll watchers—self-appointed election vigilantes from both parties and from independent groups—have planted themselves in voting precincts across the country today to look over the shoulders of harried election officials and ensure that votes for their candidates get counted. The Romney campaign’s effort, dubbed Project ORCA, features something unusual: a smartphone app with a “voter fraud” button that poll watchers can use to instantly alert a squad of campaign lawyers stationed at the Boston Convention Center.


Ryan Williams, a Romney spokesman, says many of the campaign’s 34,000 volunteers watching over polls in hotly contested states have the app. They’re instructed not to talk to voters, says Williams, but looking over a poll worker’s shoulder to see who’s been checked off the voter list is O.K. The poll watchers are also checking whether voting machines work. If they suspect trouble of any kind (such as someone trying to vote twice), they hit the “voter fraud” button. That dials Boston, where lawyers will decide whether to file a lawsuit.













Voter fraud is rare. According to Jane Mayer at the New Yorker, there have been only seven convictions for fraud by impersonation since 2000. Democrats see the GOP’s measures as an effort to suppress voting, not protect it. In a memo circulated last week, Robert Bauer, general counsel to the Obama campaign, used blunt language to describe the GOP strategy: “Either directly, through its vendors, or in close association with allied organizations, the Republicans are attempting to disrupt the electoral process and create obstacles to the fair and effective exercise of the right to vote. All of this is done in the name of investigating and combating ‘fraud.’”


The Romney campaign isn’t just using its ORCA app to alert Boston to funny business, though. They’re also using it to see if someone on their list hasn’t voted yet. Those who haven’t turned out might get a call at home. Or the campaign could dispatch a surrogate to a local radio station to ask for votes.


Businessweek.com — Top News



Read More..

Officials: New mass graves found in Ivory Coast
















ABIDJAN, Ivory Coast (AP) — Up to 10 new mass graves have been discovered near the site of a July attack on a camp for displaced people, officials said Tuesday, amid allegations that initial casualty totals were downplayed to mask killings carried out by the national army.


Rights groups claim summary executions were carried out by the Republican Forces of Ivory Coast, known by its French acronym of FRCI. Last month, officials found six bodies in a well close to the former campsite in the western town of Duekoue.













Government, army and U.N. officials toured 10 more graves in the same area on Saturday, said Paul Mondouho, vice-mayor of Duekoue. He said the graves had first been identified by civilians, and that officials did not know the number of bodies they contained because they had not yet been properly exhumed.


“People were suspecting the presence of bodies in these graves because of the smell coming out of them and because of the shoes we saw nearby,” Mondouho said.


Prosecutor Noel Dje Enrike Yahau, who is based in the commercial capital of Abidjan, confirmed that multiple new graves had been discovered but could not provide details. U.N. officials and the local prosecutor in charge of investigating the suspected killings could not be reached Tuesday.


U.N. spokeswoman Sylvie van den Wildenberg confirmed that U.N. forces helped Ivorian authorities secure a perimeter around 10 wells “similar to the one in which six bodies were found,” and that “some of those wells are suspected mass graves.”


She stressed that Ivorian authorities were leading the investigation but that the U.N. was able to provide assistance.


Army spokesmen could not be reached Tuesday. The Justice Ministry has previously vowed to investigate the discovery of the initial grave.


On the morning of July 20, a mob descended on the U.N.-guarded Nahibly camp, which housed 4,500 people displaced by violence in Ivory Coast, burning most of the camp to the ground. Officials said at the time that six people were killed.


The attack was prompted by the shooting deaths of four men and one woman on the night of July 19, according to local officials and residents. In response a mob of some 300 people overran the camp on the morning of July 20 after the perpetrators of the shootings reportedly fled there.


The victims in the July 19 attack lived in a district dominated by the Malinke ethnic group, which largely supported President Alassane Ouattara in the disputed November 2010 election. The camp primarily housed members of the Guere ethnic group, which largely supported former President Laurent Gbagbo.


Gbagbo’s refusal to cede office despite losing the election to Ouattara sparked months of violence that claimed at least 3,000 lives.


Albert Koenders, the top U.N. envoy to Ivory Coast, said one week after the attack that U.N. security forces had been inside and outside the camp at the time but that no Ivorian security forces were present. He said the U.N. forces decided not to fire at a large group of people that were attacking the camp in order to avoid “a massacre.”


Several witnesses have said soldiers and traditional hunters, known as dozos, participated in the attack on the camp. Both military and dozo leaders have denied the claims, saying they had tried to protect the camp.


In a statement released Friday, the International Federation for Human Rights, known by its French acronym of FIDH, said it had information — including the preliminary results of autopsies — confirming that the six bodies found in October were men who had been summarily executed by the army.


“The disappearance of dozens of displaced persons after the attack, as well as confirmation of cases of summary and extra-judicial executions, suggest a much higher victim rate than the official figures report,” said the organization, which counts Ivorian civil society groups among its members.


Duekoue was one of the hardest-hit towns during the post-election violence. The U.N. has established that at least 505 people were killed in and around the town, including during a notorious March 2011 massacre that claimed hundreds of lives and was allegedly carried out by fighters loyal to Ouattara.


Duekoue residents belonging to ethnic groups that supported Gbagbo have long complained about abuses carried out by the FRCI, with some pointing to the direct involvement of the local commander, Kone Daouda. FIDH said in its statement that Daouda had been transferred following the discovery of the grave in October, and called for him to be interrogated over the matter.


The group also said two FRCI members were being “actively sought” after failing to return to their barracks on Oct. 16, noting that they are believed to have fled to neighboring Burkina Faso.


Africa News Headlines – Yahoo! News



Read More..

Apple sells 3 million iPads over first weekend
















SAN FRANCISCO/NEW YORK (Reuters) – Apple Inc sold 3 million of its new iPads in the first three days the tablet computers were available, driving optimism for a strong holiday quarter despite intensifying competition.


Sales of the 7.9-inch iPad mini and fourth-generation 9.7-inch version, both Wi-Fi only models, were double the first-weekend sales of the Wi-Fi iPad sold in March, Apple said on Monday.













Apple did not break out numbers for the crucial iPad mini, a smaller version of the original tablet designed to spearhead its foray into a segment now dominated by Amazon.com Inc and Google Inc.


Analysts estimate that about 2.3 million of the new iPads sold over the weekend were the mini-tablets, surpassing expectations of 1 million to 1.5 million.


Wall Street, which was disappointed with Apple’s latest quarterly earnings, had been looking to the iPad mini to boost demand during the crucial year-end holiday shopping season as competition reaches a fever pitch. Microsoft Corp became the latest major entrant to the market last month with the Windows-driven Surface.


While lines for the new iPads appeared lighter than usual when they began selling at stores on Friday, the company said demand was so strong that it “practically sold out of iPad minis.”


Apple had never before introduced two different iPad models in one quarter. Raymond James analyst Tavis McCourt said that while the sales number looked good, the company would need to sell another 20 million iPads this quarter to meet his estimate.


“There’s still a lot of wood to chop in the quarter,” McCourt said.


The company said it had shipped many of the new iPads ordered before the release date, but would not send some out until later this month.


Apple had sold 3 million iPads in March, including those with cellular connections as well as Wi-Fi only models.


“We set a new launch weekend record and practically sold out of iPad minis,” Apple Chief Executive Tim Cook said in a statement. “We’re working hard to build more quickly to meet the incredible demand.”


HOLIDAY SALES CRUCIAL


Apple shares were up 1.7 percent at $ 586.50 in morning trading on Nasdaq, still down more than 16 percent from a record high set in September.


The 7.9-inch iPad mini marks Apple’s first foray into the smaller-tablet segment and is the company’s first major new device since the death of co-founder Steve Jobs last year.


Versions of iPads with both Wi-Fi and cellular connections will not ship in the United States for another few weeks. And both will hit more countries later this year.


The iPad mini takes aim at Google’s Nexus 7 and Amazon’s Kindle Fire. At stores around the world, the product’s debut drew sparser crowds than previous launches did, dampening initial optimism for sales. Still, the mini attracted hundreds of people in many locations.


Apple heads into the current quarter after refreshing almost all of its product lines, from Macintosh computers to tablets.


“We believe the iPad mini has the opportunity to surpass the sales of the regular-sized iPads over the next several years,” said Topeka Capital analyst Brian White.


(Reporting by Sayantani Ghosh in Bangalore and Sinead Carew in New York; Editing by Saumyadeb Chakrabarty and Lisa Von Ahn)


Gadgets News Headlines – Yahoo! News



Read More..

Sharon Osbourne has double mastectomy-magazine
















LONDON (Reuters) – British celebrity Sharon Osbourne has had a double mastectomy after discovering she was carrying a gene that increased the risk of her developing breast cancer, she told Hello! magazine in an interview published on Monday.


Osbourne, 60, told the publication that the decision was a “no-brainer” in the end.













“As soon as I found out I had the breast cancer gene, I thought: ‘The odds are not in my favor’,” she said in remarks that also ran in the Daily Mirror tabloid.


“I’ve had cancer before and I didn’t want to live under that cloud: I decided to just take everything off, and had a double mastectomy.”


Osbourne, who put the eccentric life of her family on view in the reality TV series “The Osbournes”, said she did not want to spend the rest of her life with “that shadow hanging over me.


“I want to be around for a long time and be a grandmother to Pearl,” she added, referring to her son Jack’s first child.


“I didn’t even think of my breasts in a nostalgic way, I just wanted to be able to live my life without that fear all the time. It’s not ‘pity me’, it’s a decision I made that’s got rid of this weight that I was carrying around.”


Osbourne raised her profile by appearing as a judge on successful talent shows “The X Factor” and “America’s Got Talent”. She is married to heavy metal singer Ozzy Osbourne.


Her London publicist referred Reuters to the interview which ran in Hello! and the Daily Mirror when asked to confirm the news.


(Reporting by Mike Collett-White, editing by Paul Casciato)


Celebrity News Headlines – Yahoo! News



Read More..